Needham analyst Laura Martin reiterates AcuityAds Holdings (NASDAQ:ATY) with a Buy and maintains $2.5 price target.
HC Wainwright & Co. Maintains Buy Rating for Spero Therapeutics: Here’s What You Need To Know
HC Wainwright & Co. has decided to maintain its Buy rating of Spero Therapeutics (NASDAQ:SPRO) and raise its…